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intervention may help reinforce health policy worldwide. METHODS: Using a 
Markov model, we performed a cost-effectiveness analysis to estimate the costs, health 
gains, and incremental cost-effectiveness (international dollars [I$] per quality-adjusted 
life year [QALY] gained) of an exercise training program in HF class II and III NYHA 
patients, comparing with standard treatment, assuming a public system perspective in 
Brazil. QALYs were estimated from an outpatient cohort of 318 patients. Treatment 
efﬁcacy was obtained from controlled trials and meta-analysis; treatment costs were 
derived from published data and National Health System reimbursement rates in 
2008. Exercise training costs were obtained from a cardiac rehabilitation center. 
Robusteness of results was tested by Monte Carlo simulation and sensitivity analysis. 
RESULTS: Considering a 35% reduction of mortality with exercise training and an 
annual cost of I$ 1,176 per patient, this strategy had a total cumulative cost of I$ 
25,856 and 4.95 QALYs. Comparing with standard treatment, which had a total cost 
of I$ 16,758 and 4.34 QALYs, the incremental cost per QALY of exercise training 
was I$ 14,965. Results were sensitive to intervention-related costs and effect size. 
Considering the results of the HF-ACTION trial, in a time-limited exercise program 
with a 11% combined event (all-cause mortality or hospitalization) reduction and an 
exercise cost of I$ 470 per patient, incremental cost-effectiveness ratio would be I$ 
19,828/QALY. CONCLUSIONS: Under several assumptions, exercise training 
appeared to be cost-effective, and to offer good value for money compared to other 
well-accepted HF treatment strategies. The results support implementing such inter-
vention as part of public health efforts to improve HF management.
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OBJECTIVES: In the INFORCE study, treatment with ezetimibe/simvastatin (Eze/
Simva) 10/40 mg/day was superior to doubling the statin dose in reducing total cho-
lesterol (TC) among inpatients with suspected coronary events already receiving a 
statin (stratiﬁed into 3 potency strata at baseline). The purpose of this analysis was 
to evaluate the cost-effectiveness of Eze/Simva in this population by translating reduc-
tions in the observed TC: high-density lipoprotein cholesterol ratio into projected 
lifetime costs and beneﬁts. METHODS: A Markov model (Cook et al 2004) was used 
to project lifetime costs and beneﬁts based on patients’ cardiovascular risk factor 
proﬁles and actual lipid values at baseline and endpoint (12 weeks). Inputs for car-
diovascular event costs and age-speciﬁc utilities for health states were based on a 2006 
National Institute of Health and Clinical Excellence submission for Eze and age-spe-
ciﬁc non–CHD mortality rates (2006) derived from UK Ofﬁce of National Statistics 
mortality data. RESULTS: At baseline, the Eze/Simva group (N  195) had a higher 
mean [SD] TC (4.33 [0.89] mmol/L) than the double-statin group (N  189; 4.16 
[0.80] mmol/L). In the pooled-data analysis adjusted for baseline proﬁle, Eze/Simva 
conferred 0.218 discounted (3.5%) incremental quality-adjusted life year (QALY) at 
a discounted (3.5%) incremental cost of £2,524, for an Incremental Cost-Effectiveness 
Ratio (ICER) of £11,571/QALY. Similar data were observed in each stratum of statin 
LDL-C–lowering potency, with ICER values £15,000/QALY for each comparison 
of Eze/Simva to statins: Eze/Simva was cost-effective in the low-potency (£13,552/
QALY), medium-potency (£11,930/QALY), and high-potency (£10,148/QALY) statin 
strata in adjusted analyses. On bootstrapping analysis, the ICER for Eze/Simva therapy 
was £20,000/QALY in 99% of replicates for the adjusted analysis. CONCLUSIONS: 
Among UK inpatients evaluated for coronary events, switching to Eze/Simva 10/40 mg 
is projected to be a cost-effective treatment alternative (vs doubling the statin dose) 
based on a commonly applied UK ICER threshold (£20,000–£30,000).
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OBJECTIVES: Statin dose escalation to reach low-density lipoprotein cholesterol 
(LDL-C) goals is an established practice. This study analyzes the health economic 
impact of titrating patients to a target LDL-C of 100 mg/dl as recommended by current 
guidelines. First-line brand rosuvastatin and ﬁrst-line generic simvastatin protocols are 
compared. METHODS: A published state-transition model was used, linking age, 
smoking status, systolic blood pressure, and total cholesterol (TC) to fatal CVD risk 
using the Belgian SCORE (primary prevention) and Framingham (secondary preven-
tion) equations. Non-fatal risk was based on landmark prevention trials. Patient 
LDL-C levels (mean/SD, before/after treatment start) were based on the STELLAR 
trial for simvastatin 20/40/80 mg and rosuvastatin 10/20/40 mg. Hence, consistent 
with the STELLAR trial a baseline LDL-C value (mg/dl) of (mean / SD) 189 / 19 
was applied. Other patient data were based on the DISCOVERY-BELUX trial that 
included Belgian patients. Resource use and unit costs were based on literature and 
ofﬁcial reimbursement tariffs. Patient groups starting on either rosuvastatin (10 mg) 
or simvastatin (20 mg) were compared. Patients not reaching LDL-C target were 
switched to the next higher dose of the same statin. Simvastatin 80 mg patients not 
reaching target were switched to 20 mg and if needed 40 mg of rosuvastatin. Cost-
effectiveness results were reported as EUR 2009 (direct medical costs from a public 
payer perspective) per Life Year gained (LYg) for a time horizon of 20 years. 
RESULTS: EUR/LYg values of 56,481 and 43,884 were found for respectively primary 
and secondary settings, well below some of the ICER values reported for other health 
care interventions attracting public reimbursement. Model explorations indicated that 
cost-effectiveness improved for lower LDL-C targets and higher baseline patient LDL-
C levels. CONCLUSIONS: Exclusive titration by rosuvastatin compared to starting 
patients ﬁrst on simvastatin, is likely to be cost-effective in patients with elevated 
LDL-C levels both in primary and secondary prevention.
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OBJECTIVES: This study aims to verify the economic feasibility of clopidogrelaspirin 
combination therapy by comparing the reduction in ischemic heart disease develop-
ment, and corresponding costs of aspirin monotherapy and clopidogrelaspirin com-
bination therapy (CT) in Korean acute coronary syndrome (ACS) patients. METHODS: 
We conducted a cost-effectiveness analysis of 3-years clopidogrelaspirin CT in ACS 
patients from a social perspective, taking into account all direct medical costs, direct 
non-medical costs, and indirect costs that occur during the course of clopidogrelaspirin 
CT and compared this to aspirin monotherapy. The effect of clopidogrel addition was 
applied, based on data from the Clopidogrel in Unstable angina to prevent Recurrent 
ischemic Events (CURE) study. The transition probability of Markov model was esti-
mated using health insurance claim data and records in the Korean Cause of Death 
Registry for the years 2001–2003. RESULTS: The long-term Markov model analysis 
revealed that the effect of clopidogrelaspirin CT compared with aspirin monotherapy 
in ACS patients was 0.207 life-years gained (LYG) and that the incremental cost-
effectiveness ratio analyzed as incremental costs per LYG was US$ 5,154.07. In addi-
tion, sensitivity analysis demonstrated that the relative risk and discount rate for 
cardiovascular events (acute myocardial infarction, stroke and cardiovascular death) 
were the variables that mainly affected the study results. CONCLUSIONS: A 38-year 
follow-up study of the 3-years effect of clopidogrelaspirin CT in Korea reveals that 
clopidogrel CT is a cost-effective alternative to aspirin monotherapy. Additionally, 
these results provide an economic justiﬁcation for recommending clopidogrel CT in 
the treatment of ACS patients within the Korean context.
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OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁable cardiovascular risk factor. Ivabradine is a speciﬁc HR lowering agent 
indicated in chronic stable angina (SA) patients with normal sinus rhythm, contrain-
dicated or intolerant to beta-blockers. This study aimed to estimate the cost-effective-
ness of ivabradine versus generic amlodipine in such patients, from the Finnish societal 
perspective. METHODS: A Markov chain Monte Carlo stochastic simulation model 
was used to estimate the inﬂuence of HR lowering in cardiovascular morbidity and 
mortality and its economic consequences. Ivabradine, 7.5 mg twice a day, was com-
pared against amlodipine, 10 mg once a day. HR distribution was modelled as a 
gamma function and survival and time to hospitalization were modelled with weibull 
functions. Only patients with resting HR       70 bpm were included. Events considered      
were acute myocardial infarction, stroke, heart failure and death, as well as revascu-
larization procedures (coronary artery bypass graft and percutaneous coronary inter-
ventions). Finnish setting was considered, including only direct costs, derived from the 
2006 Finnish Guidelines for Healthcare Unit Costs. Effectiveness was measured in life      
years (LY) and quality-adjusted life years (QALY). Time horizon was set at 20 years 
and discount rate was 5%/year for costs and effectiveness. RESULTS: For each 100 
patients using ivabradine in comparison with amlodipine we estimate a 36 LYs 
(95%CI: [18;57]) or 30 QALYs (95%CI: [17;47]) gain. Annual incremental cost per 
patient was a226 (95%CI: [201;243]). Incremental cost-effectiveness ratios for ivabra-
dine utilization were a12,886/LY and a15,060/QALY. For high levels of certainty     
(90%), willingness to pay for ivabradine’s beneﬁts didn’t exceed a24,000, regardless 
of the effectiveness measure considered. CONCLUSIONS: Ivabradine is a cost-
 effective alternative for the treatment of SA when compared to generic amlodipine     
in a Finnish setting of patients with contraindication or intolerance to beta-blockers         
and resting HR  70 bpm. 
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OBJECTIVES: High resting heart rate (HR) has been increasingly accepted as a 
modiﬁable cardiovascular risk-factor. Ivabradine has shown speciﬁc HR lowering 
properties and is indicated in chronic stable angina (SA) patients with normal sinus 
rhythm having a contraindication or intolerance for beta-blockers. The aim of this 
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study was to estimate the cost-effectiveness of ivabradine versus diltiazem as an alter-
native bradycardic agent in these patients. METHODS: A Markov chain Monte Carlo 
simulation model was used to estimate the effect of HR lowering on cardiovascular 
outcomes, including the economic consequences of ivabradine, 7.5 mg twice daily 
versus diltiazem, 240 mg once a day. Included patients had resting HR  70 bpm.  
Outcome events considered were acute myocardial infarction, stroke, heart failure and 
death, as well as revascularization procedures (coronary artery bypass graft and per-
cutaneous coronary interventions). HR distribution was modelled as a gamma func-
tion and survival and time to hospitalization were modelled with weibull functions. 
Health outcomes were measured in life years (LY) and quality-adjusted life years 
(QALY). Time-horizon was set at 20 years and health outcomes and costs were dis-
counted at 1.5% and 4%, respectively. The analysis was conducted following the 
Dutch guidelines for pharmacoeconomic research. RESULTS: For each 100 patients 
assumed to use ivabradine or diltiazem, ivabradine was estimated to gain 44 LY 
(95%CI: [24;70]) and 36 QALY (95%CI: [22;52]) versus diltiazem. Annual incremen-
tal per patient cost of ivabradine versus diltiazem was estimated at a178 (95%CI: 
[138;207]). The incremental cost-effectiveness ratios for ivabradine versus diltiazem 
were estimated at a7990 per LY and a9897 per QALY gained. The probability of   
accepting ivabradine following the informal Dutch willingness-to-pay threshold of 
a20,000 per QALY was estimated at 99%. CONCLUSIONS: Ivabradine was found 
to be a cost-effective alternative for the treatment of SA in patients with resting HR 
 70 bpm with contraindication or intolerance for beta-blockers.    
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OBJECTIVES: The aim of this study was to assess the clinical and economic beneﬁts 
of the stroke units compared with conventional care. METHODS: A Markov model 
was developed. Four clinical conditions were deﬁned : ﬁrst ischaemic event, ﬁrst cere-
bral haemorrhage, recurrent ischaemic , recurrent haemorrhagic. Three lines of man-
agement were identiﬁed after hospitalisation: rehabilitation, home, and geriatric 
institutions. Three levels of incapacity were identiﬁed using the Barthel index. 
The clinical beneﬁt was measured as survival without loss of independence (Barthel 
95–100). The relative risks of death or institutionalisation, or death or dependence 
after passage through a stroke unit were analysed in comparison with conventional 
hospital services from the data available in the Cochrane meta-analyse on stroke 
units. All of the cost calculations were made from the perspective of the health care 
system. Expenditures were discounted at a rate of 5%. RESULTS: The mean cost per 
patient at 5 years was a30,983 in a conventional care unit and a34,638. in a stroke 
unit.After 5 years, the cumulative expenditure for the care of 120,000 patients 
in conventional care units was a3.710 million. Where care is generalised in a stroke 
unit, this ﬁgure increases to a4.160 million. In the 5 years following hospitalisation, 
patients cared for in stroke units survive for more trimesters without sequalae than 
those cared for conventionally (11.6 vs. 8.28). Comparison of the additional cost and 
added efﬁcacy gave a ratio of a1359 per year of life gained without disability (Barthel 
95–100). a513). CONCLUSIONS: The cost-effectiveness ratio between for stroke 
units is much lower than the threshold for cost-effectiveness considered acceptable by 
the international scientiﬁc community (a53,400). This extremely favourable ratio 
could justify organisational changes and the establishment of stroke units in the hos-
pital environment.
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OBJECTIVES: In Russian Federation (RF) just 25% of patients with hypertension 
(HT) reach target blood pressure goals. Moreover, patients with concomitant Type-2 
diabetes have a small chance of successful treatment. Direct Renin Inhibitors (DRI) 
—the newest class of antihypertensive drugs with clinically important nephroprotec-
tive properties. The aim of the study was to assess cost-effectiveness ratio of DRI 
aliskiren in treatment of patients with HT, Type-2 diabetes and nephropathy in Russia. 
METHODS: A lifetime Markov model basing on results of AVOID study was devel-
oped. Incremental cost-effectiveness ratio (ICER) of aliskiren  losartan vs placebo  
losartan was assessed. In the model it is conservatively assumed that no additional 
beneﬁt of aliskiren is extended to periods after 6 months according to 6-months 
AVOID trial. Direct medical costs were calculated basing on tariffs of Federal Obliga-
tory Medical Insurance Fund of the RF. Health outcomes were quality-adjusted life 
years (QALY) and life-years gained (LYG). Clinical and economic outcomes were 
discounted at 3.5%. RESULTS: Cost-effectiveness of aliskiren for 60-years old 
patients in HT, Type-2 diabetes and nephropathy is within the range of 280 thous. 
rubles/LYG (300 thousand rubles/QALY) for early overt nephropathy to 525 thou-
sand rubles/LYG (570 thousand rubles/QALY) for microalbuminuria. Sensitivity 
analysis depending on age of patients between 55–65 years old demonstrates non-sig-
niﬁcant difference (o 5%) of ICER. In accordance with the budjet of the RF in 2009, 
gross domestic product per capita is 360 thous. rubles and ICER is within the range 
of values that are considered acceptable for Russian Health Care system. CONCLU-
SIONS: ICER of aliskiren usage in antihypertensive treatment of patients with HT, 
Type 2 diabetes and nephropathy is comparable with ICER of other cardiovascular 
drugs included into Russian reimbursement. So aliskiren have to be available for 
countrywide health care systems regardless of age of patients.
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OBJECTIVES: Translate clinical beneﬁts of raising HDL-C into life years saved (LYS) 
using randomized placebo controlled clinical trial data of NIASPAN as monotherapy 
(NER), or in combination with statin (NER/S), in patients with inadequate HDL-C 
control. METHODS: Two analyses were undertaken: translation of clinical beneﬁts 
into survival beneﬁts using NER, and NER/S, in patients lacking optimal HDL-C 
control. Validated equations (HDL-C Mortality Equations), were used to translate 
HDL-C and LDL-C into reductions in mortality. NER effects are taken from placebo-
controlled trials. Comparative efﬁcacy of NER/S is taken from seven clinical trials 
with NER/S versus a statin only. The treatment arms were categorized by dose and 
the weighted average effects were calculated for change from baseline in HDL-C as 
and LDL-C. RESULTS: Applying the regression parameter estimates from the vali-
dated equation (i.e., 1.02 for LDL-C and 1.51 for HDL-C) to NER trial results, and 
after adjusting for the placebo effect, yields the estimated percent reductions in car-
diovascular events, 23.22%, 34.89% and 36.4% at 1000 mg/day, 1500 mg/day and 
2000 mg per day, respectively. Translating increases in HDL-C by adding NER/S after 
adjusting for the statin alone effect are 0.10 mmol/L, 0.2213 mmol/L and 0.2063 mmol/
L for 1,000 mg, 1,500 mg and 2,000 mg per day, yielding 27.16, 59.75, and 55.7 lives 
saved per 10,000 patients. The Prospective Studies Collaborative report a 0.33 mmol/
L increase in HDL-C is associated with about a third (33%) lower IHD mortality. 
Weighted average increases in HDL-C, with NER/S are 0.318 mmol/L. Applying 
change in HDL-C values using the HDL-C Mortality Equations with bootstrapping, 
the hazard ratios are reduced by 29% [95% CI: 0.34 – 0.23], 30% [95% CI: 
0.35 – 0.24] and 32% [95% CI: 0.38 – 0.26]. CONCLUSIONS: Nicotinic acid 
increases survival in patients with low HDL-C when used as NER or NER/S.
PCV101
IS PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN 
PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING 
PERCUTANEOUS CORONARY INTERVENTION FROM THE 
PERSPECTIVE OF THE GERMAN HEALTH CARE SYSTEM?  
A MODEL-BASED ANALYSIS
Davies A1, Sculpher M2, Schmitt C3, Barrett A4, Clouth J5, McCollam PL6, Bakhai A7
1Oxford Outcomes (UK), Oxford, England, 2University of York, York, UK, 3Eli Lilly and 
Company, Windlesham, Surrey, UK, 4Eli Lilly and Company Ltd, Windlesham, Surrey, UK, 
5Lilly Deutschland GmbH, Bad Homburg, Germany, 6Eli Lilly and Company, Indianapolis, IN, 
USA, 7Barnet & Chase Farm NHS Trust, Barnet, UK
OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percuta-
neous coronary intervention (PCI), the TRITON-TIMI 38 trial demonstrated that 
treatment with prasugrel vs. clopidogrel was associated with signiﬁcantly reduced rates 
of atherothrombotic events, though with increased risk of bleeding. We evaluated the 
long-term cost-effectiveness of a 12-month treatment with prasugrel vs. clopidogrel in 
the trial population, excluding patients with prior transient ischemic attack or stroke, 
from the perspective of the German health care system. METHODS: A Markov model 
was developed based on risk equations for cardiovascular death, myocardial infarction 
(MI) or stroke, bleeding, and rehospitalisation, derived from TRITON-TIMI 38 data 
(N  13,608 patients). Hospital readmissions captured during the trial in all patients 
from 8 countries (N  6705) were assigned to German diagnosis related groups, and 
hospitalisation costs continued to accrue beyond 12 months to all surviving patients. 
Long term survival and quality adjusted survival were estimated for the life-time of each 
patient. RESULTS: At 12 months, a difference in drug costs between prasugrel and 
clopidogrel of 105 (branded clopidogrel) to a416 (generic clopidogrel) per patient 
was partially or totally offset by hospital cost savings (a129 per patient) due princi-
pally to reduced rates of revascularization. In the longer-term, prasugrel was associated 
with higher total costs (a42 to a353 per patient), life expectancy gains of 0.07 years, 
due primarily to the reduced rate of MI, and 0.05 additional QALYs, resulting in 
incremental costs per life year saved and per QALY gained of a606 to a5074 and a799 
to a6689, respectively. Probabilistic sensitivity analysis indicated that prasugrel has a 
q79 to 88% probability of being more cost-effective than clopidogrel at a willingness 
to pay of a30,000 per QALY. CONCLUSIONS: Prasugrel given for up to 1 year in 
ACS-PCI patients is likely to be considered a highly cost-effective treatment strategy.
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OBJECTIVES: Albuminuria has been proven to be associated with renal disease 
progression and cardiovascular (CV) events. Limited evidence exists on the cost- 
